Related references
Note: Only part of the references are listed.The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma
Qingqing Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Novel Pyridine-Based Hydroxamates and 2′-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity
Clemens Zwergel et al.
CHEMMEDCHEM (2021)
Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer
Yuhao Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents
Xiaopeng Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Epigenetic polypharmacology: A new frontier for epi-drug discovery
Daniela Tomaselli et al.
MEDICINAL RESEARCH REVIEWS (2020)
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
Shipeng He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells
Annalisa Romanelli et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity
Junyu Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer
Giulia Stazi et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors
Xuewu Liang et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo
Qing-Qing Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
Jie Zang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer
Heba M. Hesham et al.
MEDICINAL RESEARCH REVIEWS (2018)
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
Shipeng He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors
Guoqiang Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Phthalazino[1,2-b]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells
Guo-Hai Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Elena Ceccacci et al.
BRITISH JOURNAL OF CANCER (2016)
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Yang Hai et al.
NATURE CHEMICAL BIOLOGY (2016)
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Y. Shi et al.
ANNALS OF ONCOLOGY (2015)
Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit
Charles M. Marson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors
Marije Slingerland et al.
ANTI-CANCER DRUGS (2014)
Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
De-Si Pan et al.
MEDCHEMCOMM (2014)
Non-Cell-Autonomous Tumor Suppression by p53
Amaia Lujambio et al.
CELL (2013)
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Jay H. Kalin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
HDAC inhibitor-based therapies: Can we interpret the code?
Maria New et al.
MOLECULAR ONCOLOGY (2012)
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
Missak Haigentz et al.
ORAL ONCOLOGY (2012)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Cliona Grant et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Stage-specific sensitivity to p53 restoration during lung cancer progression
David M. Feldser et al.
NATURE (2010)
Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents
Karita Peltonen et al.
PLOS ONE (2010)
Radiosensitizing Potential of Epigenetic Anticancer Drugs
Harlinde De Schutter et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations
Antonello Mai et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells
F. Condorelli et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Restoration of p53 to limit tumor growth
Wenge Wang et al.
CURRENT OPINION IN ONCOLOGY (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Wild-type p53: Tumors can't stand it
Michael B. Kastan
CELL (2007)
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Aime A. Levesque et al.
CARCINOGENESIS (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
A phase II study of depsipeptide in refractory metastatic renal cell cancer
Walter M. Stadler et al.
CLINICAL GENITOURINARY CANCER (2006)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Histone deacetylase inhibitors
TA Miller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Share Paper
